BTK-selective covalent kinase inhibitor
Ph. I completed in HV, in Ph. II
SBDD from reversible BTK inhibitor and opt.
J. Med. Chem., Mar. 4, 2020
Novartis, Basel, CH
Remibrutinib
1 min read
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
Search By Structure
- CC-92480
- “PROTAC 6”
- GSK620
- Merck hArg1 inhibitor
- Merck IDO1 inhibitor
- Constellation EZH2 inhibitor
- Arcus CD73 inhibitor
- MK-6884
- Sulfopin
- M3814
- Remibrutinib
Molecules of the Month
2023
2022
2021
2020